Milan G Chheda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1572847/publications.pdf

Version: 2024-02-01

25 papers 1,116 citations

933447 10 h-index 18 g-index

28 all docs 28 docs citations

times ranked

28

2258 citing authors

#	Article	IF	CITATIONS
1	Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell, 2021, 39, 509-528.e20.	16.8	327
2	PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem Cells and Gliomas. Cancer Cell, 2010, 17, 497-509.	16.8	224
3	Zika virus has oncolytic activity against glioblastoma stem cells. Journal of Experimental Medicine, 2017, 214, 2843-2857.	8.5	179
4	ZFHX4 Interacts with the NuRD Core Member CHD4 and Regulates the Glioblastoma Tumor-Initiating Cell State. Cell Reports, 2014, 6, 313-324.	6.4	106
5	Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress. Cell Reports, 2018, 22, 512-522.	6.4	74
6	Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. Neuro-Oncology, 2020, 22, 470-479.	1.2	49
7	Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade. JCI Insight, 2021, 6, .	5.0	46
8	CHD4 regulates the DNA damage response and RAD51 expression in glioblastoma. Scientific Reports, 2019, 9, 4444.	3.3	33
9	Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base. Journal of Neuro-Oncology, 2017, 131, 593-601.	2.9	27
10	The impact of systemic precision medicine and immunotherapy treatments on brain metastases. Oncotarget, 2019, 10, 6739-6753.	1.8	13
11	A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma. Neuro-Oncology Practice, 2022, 9, 193-200.	1.6	11
12	Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry. JCI Insight, 2021, 6, .	5.0	10
13	Using Epigenetic Reprogramming to Treat Pediatric Brain Cancer. Cancer Cell, 2017, 31, 609-611.	16.8	5
14	Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators. Neurosurgery, 2021, 89, 129-132.	1.1	5
15	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. Neuro-Oncology Advances, 2021, 3, vdab035.	0.7	3
16	A Fyn romance: tumor cell Fyn kinase suppresses the immune microenvironment. Neuro-Oncology, 2020, 22, 746-747.	1.2	1
17	Salvage therapies for radiation-relapsed isocitrate dehydrogenase-mutant astrocytoma and $1p/19q$ codeleted oligodendroglioma. Neuro-Oncology Advances, 2021, 3, vdab081.	0.7	1
18	565â€A novel long-acting interleukin-7 agonist, NT-17, increases cytotoxic CD8+ T cells and enhances survival in mouse glioma models. , 2020, , .		1

#	Article	IF	CITATIONS
19	Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neuro-Oncology Advances, 2022, 4, vdab186.	0.7	1
20	Understanding the Impact of IDH2 Mutations on the Redox Balance of Cancer Cells. FASEB Journal, 2018, 32, 811.13.	0.5	0
21	EXTH-14. A NOVEL LONG-ACTING INTERLEUKIN-7 AGONIST, NT-17, INCREASES CYTOTOXIC CD8 CELLS AND ENHANCES SURVIVAL IN MOUSE GLIOMA MODELS. Neuro-Oncology, 2020, 22, ii89-ii89.	1.2	0
22	STEM-13. FUNCTIONAL CHARACTERIZATION OF THE ZFHX4-CHD4 INTERACTION IN GLIOBLASTOMA CANCER STEM CELLS. Neuro-Oncology, 2020, 22, ii199-ii199.	1.2	0
23	IMMU-43. ZIKA VIRUS TO TREAT GLIOMA: TURNING COLD TUMORS HOT. Neuro-Oncology, 2020, 22, ii114-ii114.	1.2	0
24	STEM-17. NOT ALL GBM STEM CELLS ARE EQUAL: IMPLICATIONS FOR RESEARCH AND THERAPY. Neuro-Oncology, 2020, 22, ii199-ii200.	1.2	0
25	COVD-31. THE STATE OF NEURO-ONCOLOGY DURING THE COVID-19 PANDEMIC: A WORLDWIDE ASSESSMENT. Neuro-Oncology, 2020, 22, ii27-ii27.	1.2	O